PEDIATRIX MEDICAL GROUP INC (MD) Fundamental Analysis & Valuation
NYSE:MD • US58502B1061
19.525 USD
+0.06 (+0.33%)
Last: Mar 13, 2026, 10:35 AM
This MD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
Taking everything into account, MD scores 6 out of 10 in our fundamental rating. MD was compared to 101 industry peers in the Health Care Providers & Services industry. While MD has a great profitability rating, there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on MD. This makes MD very considerable for value investing!
1. MD Profitability Analysis
1.1 Basic Checks
- MD had positive earnings in the past year.
- MD had a positive operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: MD reported negative net income in multiple years.
- In the past 5 years MD always reported a positive cash flow from operatings.
1.2 Ratios
- MD's Return On Assets of 7.36% is amongst the best of the industry. MD outperforms 87.13% of its industry peers.
- Looking at the Return On Equity, with a value of 19.10%, MD belongs to the top of the industry, outperforming 87.13% of the companies in the same industry.
- Looking at the Return On Invested Capital, with a value of 9.88%, MD belongs to the top of the industry, outperforming 80.20% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for MD is in line with the industry average of 8.98%.
- The last Return On Invested Capital (9.88%) for MD is above the 3 year average (8.21%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.36% | ||
| ROE | 19.1% | ||
| ROIC | 9.88% |
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
1.3 Margins
- Looking at the Profit Margin, with a value of 8.64%, MD belongs to the top of the industry, outperforming 91.09% of the companies in the same industry.
- MD's Profit Margin has improved in the last couple of years.
- The Operating Margin of MD (12.07%) is better than 84.16% of its industry peers.
- In the last couple of years the Operating Margin of MD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.07% | ||
| PM (TTM) | 8.64% | ||
| GM | N/A |
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. MD Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MD is creating some value.
- MD has less shares outstanding than it did 1 year ago.
- MD has less shares outstanding than it did 5 years ago.
- MD has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 2.03 indicates that MD is not a great score, but indicates only limited risk for bankruptcy at the moment.
- MD has a Altman-Z score (2.03) which is in line with its industry peers.
- MD has a debt to FCF ratio of 2.36. This is a good value and a sign of high solvency as MD would need 2.36 years to pay back of all of its debts.
- MD's Debt to FCF ratio of 2.36 is fine compared to the rest of the industry. MD outperforms 76.24% of its industry peers.
- A Debt/Equity ratio of 0.66 indicates that MD is somewhat dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.66, MD is in line with its industry, outperforming 55.45% of the companies in the same industry.
- Although MD's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 2.36 | ||
| Altman-Z | 2.03 |
ROIC/WACC1.23
WACC8.04%
2.3 Liquidity
- MD has a Current Ratio of 1.66. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
- MD has a Current ratio of 1.66. This is in the better half of the industry: MD outperforms 66.34% of its industry peers.
- A Quick Ratio of 1.66 indicates that MD should not have too much problems paying its short term obligations.
- MD has a Quick ratio of 1.66. This is in the better half of the industry: MD outperforms 68.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.66 | ||
| Quick Ratio | 1.66 |
3. MD Growth Analysis
3.1 Past
- MD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.24%, which is quite impressive.
- Measured over the past years, MD shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.01% on average per year.
- Looking at the last year, MD shows a decrease in Revenue. The Revenue has decreased by -4.92% in the last year.
- MD shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.99% yearly.
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%
3.2 Future
- The Earnings Per Share is expected to grow by 1.48% on average over the next years.
- MD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.60% yearly.
EPS Next Y10.99%
EPS Next 2Y8.08%
EPS Next 3Y2.62%
EPS Next 5Y1.48%
Revenue Next Year2.7%
Revenue Next 2Y2.49%
Revenue Next 3Y4.56%
Revenue Next 5Y4.6%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. MD Valuation Analysis
4.1 Price/Earnings Ratio
- MD is valuated reasonably with a Price/Earnings ratio of 9.62.
- MD's Price/Earnings ratio is rather cheap when compared to the industry. MD is cheaper than 91.09% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 25.71. MD is valued rather cheaply when compared to this.
- The Price/Forward Earnings ratio is 8.67, which indicates a very decent valuation of MD.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of MD indicates a rather cheap valuation: MD is cheaper than 92.08% of the companies listed in the same industry.
- MD is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.82, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.62 | ||
| Fwd PE | 8.67 |
4.2 Price Multiples
- MD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MD is cheaper than 87.13% of the companies in the same industry.
- MD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MD is cheaper than 91.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.64 | ||
| EV/EBITDA | 6.5 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of MD may justify a higher PE ratio.
PEG (NY)0.88
PEG (5Y)0.96
EPS Next 2Y8.08%
EPS Next 3Y2.62%
5. MD Dividend Analysis
5.1 Amount
- No dividends for MD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MD Fundamentals: All Metrics, Ratios and Statistics
NYSE:MD (3/13/2026, 10:35:44 AM)
19.525
+0.06 (+0.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-19 2026-02-19/bmo
Earnings (Next)05-04 2026-05-04/bmo
Inst Owners98.9%
Inst Owner Change1.24%
Ins Owners1.87%
Ins Owner Change-0.8%
Market Cap1.68B
Revenue(TTM)1.91B
Net Income(TTM)165.39M
Analysts78.67
Price Target21.93 (12.32%)
Short Float %3.53%
Short Ratio3.82
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.87%
Min EPS beat(2)-9.94%
Max EPS beat(2)39.68%
EPS beat(4)3
Avg EPS beat(4)20.9%
Min EPS beat(4)-9.94%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)17.99%
EPS beat(12)7
Avg EPS beat(12)8.59%
EPS beat(16)8
Avg EPS beat(16)5.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.49%
Min Revenue beat(2)-1.41%
Max Revenue beat(2)0.42%
Revenue beat(4)1
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.42%
Revenue beat(8)2
Avg Revenue beat(8)-1.43%
Revenue beat(12)2
Avg Revenue beat(12)-2.28%
Revenue beat(16)2
Avg Revenue beat(16)-2.52%
PT rev (1m)-5.15%
PT rev (3m)-5.15%
EPS NQ rev (1m)-0.55%
EPS NQ rev (3m)-0.55%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-1.44%
Revenue NQ rev (3m)-1.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.62 | ||
| Fwd PE | 8.67 | ||
| P/S | 0.88 | ||
| P/FCF | 6.64 | ||
| P/OCF | 6.19 | ||
| P/B | 1.94 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.5 |
EPS(TTM)2.03
EY10.4%
EPS(NY)2.25
Fwd EY11.54%
FCF(TTM)2.94
FCFY15.07%
OCF(TTM)3.16
OCFY16.17%
SpS22.29
BVpS10.08
TBVpS-4.79
PEG (NY)0.88
PEG (5Y)0.96
Graham Number21.46
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.36% | ||
| ROE | 19.1% | ||
| ROCE | 12.93% | ||
| ROIC | 9.88% | ||
| ROICexc | 13.71% | ||
| ROICexgc | 1686.9% | ||
| OM | 12.07% | ||
| PM (TTM) | 8.64% | ||
| GM | N/A | ||
| FCFM | 13.2% |
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
ROICexc(3y)10.42%
ROICexc(5y)9.77%
ROICexgc(3y)618.91%
ROICexgc(5y)394.62%
ROCE(3y)10.75%
ROCE(5y)10.43%
ROICexgc growth 3Y208.98%
ROICexgc growth 5Y85.34%
ROICexc growth 3Y17.7%
ROICexc growth 5Y11.82%
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.85
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 2.36 | ||
| Debt/EBITDA | 2.26 | ||
| Cap/Depr | 84.57% | ||
| Cap/Sales | 0.96% | ||
| Interest Coverage | 6.72 | ||
| Cash Conversion | 107.19% | ||
| Profit Quality | 152.75% | ||
| Current Ratio | 1.66 | ||
| Quick Ratio | 1.66 | ||
| Altman-Z | 2.03 |
F-Score8
WACC8.04%
ROIC/WACC1.23
Cap/Depr(3y)81.68%
Cap/Depr(5y)85.74%
Cap/Sales(3y)1.24%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
EPS Next Y10.99%
EPS Next 2Y8.08%
EPS Next 3Y2.62%
EPS Next 5Y1.48%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%
Revenue Next Year2.7%
Revenue Next 2Y2.49%
Revenue Next 3Y4.56%
Revenue Next 5Y4.6%
EBIT growth 1Y25.81%
EBIT growth 3Y4.93%
EBIT growth 5Y6.1%
EBIT Next Year16.32%
EBIT Next 3Y7%
EBIT Next 5YN/A
FCF growth 1Y36.89%
FCF growth 3Y22.56%
FCF growth 5Y7.52%
OCF growth 1Y31.23%
OCF growth 3Y17.54%
OCF growth 5Y5.79%
PEDIATRIX MEDICAL GROUP INC / MD FAQ
What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?
ChartMill assigns a fundamental rating of 6 / 10 to MD.
What is the valuation status for MD stock?
ChartMill assigns a valuation rating of 8 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.
How profitable is PEDIATRIX MEDICAL GROUP INC (MD) stock?
PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 7 / 10.
What are the PE and PB ratios of PEDIATRIX MEDICAL GROUP INC (MD) stock?
The Price/Earnings (PE) ratio for PEDIATRIX MEDICAL GROUP INC (MD) is 9.62 and the Price/Book (PB) ratio is 1.94.